Skip to main content

previous disabled Page of 3
and
  1. Article

    Open Access

    Interventions on gender equity in the workplace: a sco** review

    Various studies have demonstrated gender disparities in workplace settings and the need for further intervention. This study identifies and examines evidence from randomized controlled trials (RCTs) on interve...

    Andrea C. Tricco, Amanda Parker, Paul A. Khan, Vera Nincic, Reid Robson in BMC Medicine (2024)

  2. No Access

    Article

    Relationship Between Gestational Weight Gain and Health Service Utilization in Early Childhood: A Retrospective Cohort Study

    Gestational weight gain (GWG) outside recommended ranges can negatively impact both the woman and child. The long-term effects of below-recommended or above-recommended GWG on the child are unclear.

    Lisa M. Currie, Deshayne B. Fell, Steven Hawken in Maternal and Child Health Journal (2024)

  3. Article

    Open Access

    Assessing the quality and value of metabolic chart data for capturing core outcomes for pediatric medium-chain acyl-CoA dehydrogenase (MCAD) deficiency

    Generating rigorous evidence to inform care for rare diseases requires reliable, sustainable, and longitudinal measurement of priority outcomes. Having developed a core outcome set for pediatric medium-chain a...

    Ryan Iverson, Monica Taljaard, Michael T. Geraghty, Michael Pugliese in BMC Pediatrics (2024)

  4. Article

    Open Access

    Maternal weight and paediatric health use: mediating role of adverse birth outcomes: a retrospective cohort study

    Maternal pre-pregnancy body mass index (BMI) and gestational weight gain (GWG) above or below recommendations have been associated with increased paediatric health service utilization as well as increased risk...

    Lisa M. Currie, Hilary K. Brown, Beth K. Potter in BMC Pregnancy and Childbirth (2023)

  5. No Access

    Article

    Engaging Patients and Caregivers in an Early Health Economic Evaluation: Discerning Treatment Value Based on Lived Experience

    Traditionally, economic evaluations have engaged clinicians and policymakers; however, patients and their caregivers have insight that can ensure that the economic evaluation process appropriately reflects dis...

    Mackenzie Wilson, Kednapa Thavorn, Terry Hawrysh, Ian D. Graham in PharmacoEconomics (2022)

  6. Article

    Open Access

    Cost-effectiveness of integrated disease management for high risk, exacerbation prone, patients with chronic obstructive pulmonary disease in a primary care setting

    We evaluate the cost-effectiveness of the ‘Best Care’ integrated disease management (IDM) program for high risk, exacerbation prone, patients with chronic obstructive pulmonary disease (COPD) compared to usual...

    Andrew D. Scarffe, Christopher J. Licskai in Cost Effectiveness and Resource Allocation (2022)

  7. Article

    Open Access

    Family Experiences with Care for Children with Inherited Metabolic Diseases in Canada: A Cross-Sectional Survey

    Children with inherited metabolic diseases often require complex and highly specialized care. Patient and family-centered care can improve health outcomes that are important to families. This study aimed to ex...

    Andrea J. Chow, Michael Pugliese in The Patient - Patient-Centered Outcomes Re… (2022)

  8. Article

    Open Access

    Economic evaluation of HIV testing options for low-prevalence high-income countries: a systematic review

    This study reviewed the economic evidence of rapid HIV testing versus conventional HIV testing in low-prevalence high-income countries; evaluated the methodological quality of existing economic evaluations of ...

    Olanrewaju Medu, Adegboyega Lawal, Doug Coyle, Kevin Pottie in Health Economics Review (2021)

  9. No Access

    Article

    The Continued Need for Transparent Evidence on the Cost Effectiveness of Drugs for Rare Diseases

    Jesse Elliott, George A. Wells, Doug Coyle in PharmacoEconomics (2021)

  10. Article

    Open Access

    Stakeholder perspectives on clinical research related to therapies for rare diseases: therapeutic misconception and the value of research

    For many rare diseases, few treatments are supported by strong evidence. Patients, family members, health care providers, and policy-makers thus have to consider whether to accept, recommend, or fund treatment...

    Kylie Tingley, Doug Coyle, Ian D. Graham in Orphanet Journal of Rare Diseases (2021)

  11. No Access

    Article

    HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies

    This last decade has been marked by significant advances in the development of cell and gene (C&G) therapies, such as gene targeting or stem cell-based therapies. C&G therapies offer transformative benefits to...

    Doug Coyle, Isabelle Durand-Zaleski in The European Journal of Health Economics (2020)

  12. No Access

    Article

    Economic Evaluation of Cannabinoid Oil for Dravet Syndrome: A Cost-Utility Analysis

    Cannabinoid oils are being increasingly used to treat Dravet syndrome, yet the long-term costs and outcomes of this approach are unknown. Thus, we examined the cost effectiveness of cannabinoid oil as an adjun...

    Jesse Elliott, Bláthnaid McCoy, Tammy Clifford, Beth K. Potter in PharmacoEconomics (2020)

  13. Article

    Open Access

    Virtual follow-up and care for patients with cardiac electronic implantable devices: protocol for a systematic review

    Capacity to deliver outpatient care for patients with cardiac implantable electronic devices (CIEDs) may soon be outweighed by need. This systematic review aims to investigate the comparative effectiveness, sa...

    Shannon E. Kelly, Tammy J. Clifford, Doug Coyle, Janet Martin in Systematic Reviews (2020)

  14. Article

    Open Access

    Evaluation of the quality of clinical data collection for a pan-Canadian cohort of children affected by inherited metabolic diseases: lessons learned from the Canadian Inherited Metabolic Diseases Research Network

    The Canadian Inherited Metabolic Diseases Research Network (CIMDRN) is a pan-Canadian practice-based research network of 14 Hereditary Metabolic Disease Treatment Centres and over 50 investigators. CIMDRN aims...

    Kylie Tingley, Monica Lamoureux, Michael Pugliese in Orphanet Journal of Rare Diseases (2020)

  15. Article

    Open Access

    When piloting health services interventions, what predicts real world behaviours? A systematic concept map** review

    Modeling studies to inform the design of complex health services interventions often involves elements that differ from the intervention’s ultimate real-world use. These “hypothetical” elements include pilot p...

    Tavis Hayes, Natasha Hudek, Ian D. Graham, Doug Coyle in BMC Medical Research Methodology (2020)

  16. Article

    Open Access

    The Health System Costs of Potentially Inappropriate Prescribing: A Population-Based, Retrospective Cohort Study Using Linked Health Administrative Databases in Ontario, Canada

    The aim of this study was to determine the health system costs from hospitalizations, emergency department (ED) visits, and medications due to potentially inappropriate prescribing (PIP) in Ontario, Canada, at...

    Cody D. Black, Kednapa Thavorn, Doug Coyle, Lise M. Bjerre in PharmacoEconomics - Open (2020)

  17. Article

    Open Access

    Outcomes in pediatric studies of medium-chain acyl-coA dehydrogenase (MCAD) deficiency and phenylketonuria (PKU): a review

    Inherited metabolic diseases (IMDs) are a group of individually rare single-gene diseases. For many IMDs, there is a paucity of high-quality evidence that evaluates the effectiveness of clinical interventions....

    Michael Pugliese, Kylie Tingley, Andrea Chow in Orphanet Journal of Rare Diseases (2020)

  18. No Access

    Article

    Decision Models for Assessing the Cost Effectiveness of Treatments for Pediatric Drug-Resistant Epilepsy: A Systematic Review of Economic Evaluations

    Drug-resistant epilepsy affects about one-third of children with epilepsy and is associated with high costs to the healthcare system, yet the cost effectiveness of most treatments is unclear. Use of cannabis-b...

    Jesse Elliott, Sasha van Katwyk, Bláthnaid McCoy, Tammy Clifford in PharmacoEconomics (2019)

  19. Article

    Open Access

    A technique for approximating transition rates from published survival analyses

    Quality-adjusted-life-years (QALYs) are used to concurrently quantify morbidity and mortality within a single parameter. For this reason, QALYs can facilitate the discussion of risks and benefits during patien...

    Markian A. Pahuta, Joel Werier, Eugene K. Wai in Cost Effectiveness and Resource Allocation (2019)

  20. Article

    Open Access

    The Psychometric Properties of a Self-Administered, Open-Source Module for Valuing Metastatic Epidural Spinal Cord Compression Utilities

    Web surveys are often used for utility valuation. Typically, custom utility valuation tools that have not undergone psychometric evaluation are used.

    Markian Pahuta, Aaron Frombach, Emile Hashem, Stewart Spence in PharmacoEconomics - Open (2019)

previous disabled Page of 3